echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Chinese pharmaceutical subsidiary ganciclovir for injection passed the consistency evaluation of generic drugs

    Chinese pharmaceutical subsidiary ganciclovir for injection passed the consistency evaluation of generic drugs

    • Last Update: 2021-08-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On the 21st, China Pharmaceuticals announced that its subsidiary, Keyi Pharmaceuticals, obtained two "Approval Notices for Supplementary Drug Application for Ganciclovir for Injection" approved and issued by the State Food and Drug Administration.


    Ganciclovir is a nucleoside antiviral drug that has a broad-spectrum and highly effective inhibitory effect on herpes virus, can treat cytomegalovirus infection, and has a strong effect on hepatitis B virus and adenovirus


    As of the disclosure date of this announcement, the drug research and development expenses have invested approximately RMB 7,281,900 (unaudited)


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.